P
PRAXIS PRECISION MEDICINES INC
NASDAQ: PRAX (Praxis Precision Medicines, Inc)
Last update: 10 hours ago312.60
-11.48 (-3.54%)
| Previous Close | 324.08 |
| Open | 322.82 |
| Volume | 489,122 |
| Avg. Volume (3M) | 810,409 |
| Market Cap | 8,671,177,728 |
| Price / Sales | 842.93 |
| Price / Book | 24.04 |
| 52 Weeks Range | |
| Earnings Date | 5 Nov 2025 |
| Operating Margin (TTM) | -2,868.84% |
| Diluted EPS (TTM) | -10.66 |
| Quarterly Revenue Growth (YOY) | 1,349.10% |
| Total Debt/Equity (MRQ) | 0.24% |
| Current Ratio (MRQ) | 8.44 |
| Operating Cash Flow (TTM) | -163.91 M |
| Levered Free Cash Flow (TTM) | -90.04 M |
| Return on Assets (TTM) | -39.95% |
| Return on Equity (TTM) | -63.56% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Praxis Precision Medicines, Inc | Bearish | Bullish |
AIStockmoo Score
-0.9
| Analyst Consensus | -0.5 |
| Insider Activity | -1.0 |
| Price Volatility | -5.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 2.0 |
| Average | -0.90 |
|
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 0.16% |
| % Held by Institutions | 122.02% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Perceptive Advisors Llc | 30 Sep 2025 | 1,564,554 |
| Cormorant Asset Management, Lp | 30 Sep 2025 | 1,000,000 |
| Deerfield Management Company, L.P. | 30 Sep 2025 | 840,851 |
| Baker Bros. Advisors Lp | 30 Sep 2025 | 689,488 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 843.00 (BTIG, 169.67%) | Buy |
| Median | 450.00 (43.95%) | |
| Low | 95.00 (Wedbush, -69.61%) | Sell |
| Average | 489.56 (56.61%) | |
| Total | 8 Buy, 1 Sell | |
| Avg. Price @ Call | 272.99 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Wedbush | 12 Jan 2026 | 95.00 (-69.61%) | Sell | 275.74 |
| 05 Dec 2025 | 83.00 (-73.45%) | Sell | 247.99 | |
| BTIG | 29 Dec 2025 | 843.00 (169.67%) | Buy | 304.58 |
| 08 Dec 2025 | 507.00 (62.19%) | Buy | 270.98 | |
| Oppenheimer | 15 Dec 2025 | 750.00 (139.92%) | Buy | 276.40 |
| Guggenheim | 09 Dec 2025 | 760.00 (143.12%) | Buy | 258.13 |
| Jefferies | 09 Dec 2025 | 450.00 (43.95%) | Buy | 258.13 |
| HC Wainwright & Co. | 08 Dec 2025 | 340.00 (8.77%) | Buy | 270.98 |
| 05 Dec 2025 | 340.00 (8.77%) | Buy | 247.99 | |
| Needham | 08 Dec 2025 | 315.00 (0.77%) | Buy | 270.98 |
| 05 Dec 2025 | 304.00 (-2.75%) | Buy | 247.99 | |
| TD Cowen | 08 Dec 2025 | 353.00 (12.92%) | Buy | 270.98 |
| Truist Securities | 08 Dec 2025 | 500.00 (59.95%) | Buy | 270.98 |
| Show more | ||||
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| KELLY TIMOTHY EDWIN | 294.38 | 282.10 | 6,522 | 1,945,440 |
| MASTROCOLA LAUREN | 294.38 | 282.10 | 3,039 | 903,209 |
| NEMIROFF ALEX | 294.38 | 282.10 | 5,190 | 1,547,586 |
| SNIECINSKI MEGAN | 294.38 | 282.10 | 7,653 | 2,275,832 |
| SOUZA MARCIO | 294.38 | 288.45 | 23,388 | 6,910,174 |
| Aggregate Net Quantity | 45,792 | |||
| Aggregate Net Value ($) | 13,582,242 | |||
| Aggregate Avg. Buy ($) | 294.38 | |||
| Aggregate Avg. Sell ($) | 282.80 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| KELLY TIMOTHY EDWIN | Officer | 12 Jan 2026 | Disposed (-) | 943 | 275.74 | 260,023 |
| NEMIROFF ALEX | Officer | 12 Jan 2026 | Disposed (-) | 768 | 275.74 | 211,768 |
| SNIECINSKI MEGAN | Officer | 12 Jan 2026 | Disposed (-) | 885 | 275.74 | 244,030 |
| MASTROCOLA LAUREN | Officer | 12 Jan 2026 | Disposed (-) | 344 | 275.74 | 94,855 |
| SOUZA MARCIO | Officer | 10 Jan 2026 | Disposed (-) | 4,252 | 288.45 | 1,226,489 |
| KELLY TIMOTHY EDWIN | Officer | 10 Jan 2026 | Disposed (-) | 1,335 | 288.45 | 385,081 |
| NEMIROFF ALEX | Officer | 10 Jan 2026 | Disposed (-) | 917 | 288.45 | 264,509 |
| SNIECINSKI MEGAN | Officer | 10 Jan 2026 | Disposed (-) | 1,087 | 288.45 | 313,545 |
| MASTROCOLA LAUREN | Officer | 10 Jan 2026 | Disposed (-) | 367 | 288.45 | 105,861 |
| SOUZA MARCIO | Officer | 08 Jan 2026 | Acquired (+) | 27,640 | 294.38 | 8,136,663 |
| KELLY TIMOTHY EDWIN | Officer | 08 Jan 2026 | Acquired (+) | 8,800 | 294.38 | 2,590,544 |
| NEMIROFF ALEX | Officer | 08 Jan 2026 | Acquired (+) | 6,875 | 294.38 | 2,023,863 |
| SNIECINSKI MEGAN | Officer | 08 Jan 2026 | Acquired (+) | 9,625 | 294.38 | 2,833,408 |
| MASTROCOLA LAUREN | Officer | 08 Jan 2026 | Acquired (+) | 3,750 | 294.38 | 1,103,925 |
| Show more | ||||||
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |